A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 828 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR 5-Year-Old Boy Battling Cancer Receives Dream Come True, Sworn In As... March 24, 2021 120 years of discovery: 10 ways we’ve changed the story for... February 2, 2022 Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer May 28, 2020 “Oncometabolite” Neutralizes Immune Cells Near Tumors November 18, 2022 Load more HOT NEWS EMA Recommends Extension of Indications for Durvalumab in the Management of... How CRISPR is Changing Cancer Research and Treatment Why consistent and funded cancer policies are key to improving cancer... What the Reignited Cancer Moonshot Initiative Means for People With Cancer
